Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ciphergen Biosystems, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Proposed initial public offering of up to $86.3 mil. in common stock would fund expanded sales and marketing capabilities, R&D and corporate facilities, according to a preliminary prospectus filed with the Securities and Exchange Commission. The Palo Alto, California-based firm's ProteinChip protein analysis tool enables protein discovery, characterization and assay development for the protein-based biology research market. The current Series PBS II ProteinChip system debuted in May 1999. Ciphergen has 60 employees and in 1999 recorded sales of $5 mil., up 70.8%. A net loss of $7.7 mil. for the year compares to a loss of $8.3 mil. in 1998. The IPO is being underwritten by SG Cowen, ING Barings and Warburg Dillon Read

You may also be interested in...

Novartis Targets Ten Indications For Cosentyx

The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.

Zydus Cadila Strides Ahead With NASH Filing In India

Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.


Interview: Double Delight For ImmuPharma's Dimitriou

It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts